Search PubMed⌕ Search

Biomedical subjects

R Mordasini

Publications and source records attributed to R Mordasini.

At least 55 records · Page 3Linked to original sources
PubMed1981

[Hypertropic obstructive cardiomyopathy. A family study].

Eight patients with HOCM from the same family are presented. The clinical findings and the diagnostic and therapeutic procedures are discussed. Chest pain, palpitations and effort dyspnea were the main clinical symptoms. A characteristic systolic ejection murmur of late onset was present in all the cases. In 6 patients there were electrocardiographic signs of left ventricular hypertrophy and only 4 patients exhibited abnormal septal depolarization. Echocardiography revealed an enhanced diastolic interventricular septal to left ventricular posterior wall ratio (above 1.3), diminished left ventricular septum movement, systolic anterior motion of the mitral valve and mid systolic closure of the aortic valve. Cardiac catheterization showed a left ventricular out-flow gradient which was increased by isoproterenol infusion. In 5 patients the left ventricular angiogram disclosed systolic obliteration of the left ventricle and in 4 cases mitral regurgitation. In the therapy of HOCM, calcium antagonists are now widely used and seem to have replaced betablocking agents.

Adolescent↗
PubMed1981

Diuretic treatment and serum lipoproteins: effects of tienilic acid and indapamide.

Treatment with the commonly used diuretic, chlorthalidone, has previously been found to increase the serum low-density-lipoprotein cholesterol (LDL-C) fraction. Therefore, the effects of two new agents, tienilic acid (a combined diuretic-uricosuric) and indapamide on serum lipid and lipoprotein levels were assessed. Six weeks of treatment with tienilic acid, 250 mg/day, markedly decreased serum uric acid and significantly increased LDL-C and triglycerides in 16 men. In contrast, indapamide 2.5 mg/day, had no apparent influence on serum lipids or lipoproteins in 18 men.

Diuretics↗
PubMed1981

[HDL--the unknown with great significance].

The high density lipoproteins (HDL) play an important role in lipoprotein metabolism. In view of the results of various epidemiologic and experimental studies, their antiatherogenic potency appears to be confirmed. The antiatherogenic effect of the HDL can be chiefly explained by the following mechanisms: 1. inhibition of uptake of cholesterol-rich low density lipoproteins (LDL) by the smooth muscle cells in the arterial wall, 2. mobilization of cholesterol deposits from the cells of the arterial wall, and 3. an important role in the catabolism of triglyceride-rich lipoproteins. There are many unanswered questions concerning the role of HDL in lipoprotein metabolism. Furthermore, methodological problems with HDL determination at present reduce their clinical relevance. Determination of HDL-cholesterol should therefore be confined to borderline cases of hypercholesteremia (cholesterol 240-300 mg/100 ml) to provide a further argument for or against lipid-lowering treatment.

Alcohol Drinking↗
PubMed1981

Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrate.

The effect of bezafibrate on serum lipids, lipoproteins and the apoproteins A-I, A-II and B was studied in 18 patients with primary hypercholesterolaemia. Total cholesterol was lowered by 20% (P less than 0.05), LDL-cholesterol by 24% (P less than 0.05), and apo B by 14% (P less than 0.05), which is comparable to the effect obtained with anion exchange resins but with far fewer side-effects. HDL increased significantly during bezafibrate treatment both by measurement of HDL-cholesterol (+54%, P less than 0.05) and by the determination of HDL-apoproteins A-I (+ 19%, P less than 0.05) and A-II (+ 23%, P less than 0.05). This increase of HDL and the decrease of triglycerides was maintained for 6 weeks of placebo treatment after cessation of bezafibrate, while serum total and LDL cholesterol as well as apo B returned to their baseline levels.

Adult↗
PubMed1981

Beta-receptor-blocking agents may reverse or prevent diuretic-induced increases in serum low-density lipoprotein cholesterol.

1. The effect of treatment with a thiazide-like diuretic alone or combined with a beta-adrenoceptor blocker on serum lipoproteins was investigated in 35 patients with essential hypertension. 2. In group I (18 patients), serum low-density lipoprotein cholesterol was increased (P less than 0.001) during monotherapy with chlorthalidone (100 mg/day) but not during combined chlorthalidone--beta-blocker therapy. 3. This tendency was similar in subgroups studied with an inverse sequence of drug administration. In subgroup IA (11 men), a 22% increase (P less than 0.01) in low-density lipoprotein cholesterol after 6 weeks of chlorthalidone was reversed after use of a beta-blocker as well as chlorthalidone; in subgroup IB (five men, two post-menopausal women), low-density lipoprotein cholesterol was increased by 41% (P less than 0.05) above placebo values 6 weeks after withdrawal of the beta-blocker from combination therapy. 4. In group II (18 men), low-density lipoprotein cholesterol was increased by 13% (P less than 0.025) after 4 weeks of monotherapy with clopamide (5 mg/day) but restored to control levels 4 weeks after addition of pindolol (10 mg/day). 5. No significant changes occurred during any treatment phase in high-density lipoprotein cholesterol. 6. Certain beta-receptor blocking agents may prevent or reverse diuretic-induced increases in serum low-density lipoprotein cholesterol.

Adolescent↗
PubMed1980

[Secondary hyperlipoproteinemia induced by diuretic therapy (author's transl)].

In order to study the degree and pathogenic aspects of the secondary hyperlipoproteinemia in patients under diuretic therapy we measured serum lipids, lipoproteins and the apoproteins A1, A2 and B in 12 adults after a 4 weeks placebo period and 6 weeks of treatment with chlorthalidon. There was a significant increase in atherogenic low density lipoproteins (LDL), (18%, P less than 0.05) whereas the high density lipoprotein-cholesterol Apo A1 and A2 levels were not significantly altered. The same was true for the total serum triglyceride- and the very low density lipoprotein- and LDL-triglyceride levels. The activity of lipoprotein lipase and hepatic triglyceride lipase was slightly but not significantly increased. A delayed LDL-catabolism seems to be the most probable pathogenic mechanism underlying the Chlorthalidon-induced hyperlipoproteinemia.

Adolescent↗
PubMed1980

Apoproteins and lipids as discriminators of severity of coronary heart disease.

Serum apoprotein and lipid concentrations were measured in 63 patients undergoing coronary angiography. Thirty-eight patients had 50% or higher grade stenoses, 25 had chest pain, but no significant stenoses. Among the patients with higher grade stenoses 71% had hyperlipoproteinemias as opposed to 12% in patients without stenoses. As compared to suitable normal controls, patients with angiographically documented coronary heart disease showed significant changes in all lipid and apoprotein concentrations under study. However, differences between the two patients groups were also noted. Among these, apo A-I, A-II and B, total cholesterol and LDL cholesterol were statistically significant. These results indicate that apoprotein A and B levels, total cholesterol and LDL cholesterol are good discriminators of the severity of coronary heart disease, while HDL cholesterol is a more suitable parameter for epidemiological studies.

Adult↗
PubMed1980

Probucol in hypercholesterolemia. A double blind study.

The effect of Probucol on serum lipids, lipoproteins and the apoproteins A1, A2 and B was studied in 27 patients with primary hypercholesterolemia. After 3 months of dietary treatment and a 6 week placebo period the patients received 4 X 250 mg of Probucol or placebo per day for 4 months in a double blind design. Total and LDL-cholesterol were significantly reduced with Probucol (13% and 16% respectively) in addition to the diet. Apo B showed a 12% decrease. The HDL cholesterol concentration as well as the serum triglycerides and triglyceride-rich lipoproteins were not significantly altered. Both apo A1 and apo A2 were markedly reduced under Probucol treatment. In general the subjective and objective tolerance of the drug was good.

Adult↗
PubMed1980

Increased serum low-density lipoprotein cholesterol in men treated short-term with the diuretic chlorthalidone.

The effect of the diuretic chlorthalidone (100 mg/day for 6 weeks) on serum lipoproteins was evaluated in 37 subjects. In 19 men with essential hypertension (aged 41 +/- 3 yr), 8 normal men (26 +/- 3 yr), or all of these men considered together, chlorthalidone significantly increased serum low density lipoprotein--cholesterol (LDL-C) by 20% (p less than 0.05 to less than 0.01). There was also a tendency for increased LDL-C in seven postmenopausal women (+/- 15%) but not in three premenopausal women with essential hypertension. High density lipoprotein--cholesterol was not significantly changed in hypertensive women or normal men and decreased slightly (p less than 0.05) in hypertensive men. Apolipoproteins A-I, A-II, and B were not changed significantly in women or men. Diuretic-induced lipoprotein alterations were not associated with altered plasma volume and unrelated to variations in serum potassium, glucose, insulin levels, blood pressure, and body weight. Short-term diuretic therapy with chlorthalidone may increase serum LDL-C in young or middle-aged men with normal or high blood pressure.

Adolescent↗
PubMed1980

Salt and hypertension: data from the "Heidelberg Study".

Prevalence of hypertension and "intake" of sodium chloride (as estimated from 24-hr urinary Na-excretion) were measured in a random sample (n = 800) of 20- to 40-year-old Heidelberg men. There was a high (14%) prevalence of hypertension and a high (mean = 11.32 g) NcCl intake; both showed, however, no correlation. The lack of a NaCl/blood pressure correlation in this cross-sectional study might be due to intra- and interindividual variability of both parameters and, possibly, to a "threshold" argument concerning the etiological role of sodium in hypertension.

Adult↗
PubMed1980

Lipoprotein metabolism in nephrotic syndrome in childhood.

In nine patients with proteinuric nephrotic syndrome (NS), significant negative correlations were shown between plasma albumin and cholesterol (r=-0.85, p less than 0.005) and between plasma albumin and low density lipoprotein (LDL)-apoprotein B (ApoB) (r=-0.84, p less than 0.005), whereas there was no such correlation in ten matched ntrol patients. LDL-ApoB (182.8 +/141.2 MG/DL), cholesterol (249.3 +/-190.2 mg/dl) and triglycerides (40.8 +/- 23.5 mg/dl) were all elevated above controls. Control values: LDL-ApoB: 75.4 +/-25.0 mg/dl, -cholesterol: ll9.3 +/-27.6 mg/dl and -triglycerides: 29.2-17.9 mg/dl. The patients with proteinuric NS also exhibited a negative correlation between plasma triglyceride levels and plasma lipoprotein lipaseactiveiy (r=-0.79, p less than 0.02), which was not observed in controls. The hepatic triglycerice lipase (H-TGL) showed a mean activity of 22.2 +/- 10.7 mumol/ml FFA, which was not different form the control value of 21.2 +/-3.9 mumol/ml FFA. Not only LDL-cholesterol values were elevated in the patients with proteinuric NS, but high density lipoprotein (HDL)-cholesterol as well. HDL-cholesterol in proteinuric NS: 68.6 +/- 29.0 mg/dl, controls: 45.7 +/- 8.5 mg/dl. Twelve patients with NS in remission showed no correlation between plasma albumin and cholesterol and plasma albumin and LDL-ApoB respectively. The concentrations of LDL-ApoB (92.2 +/- 24.5 mg/dl),-cholesterol (121.7 +/- 37.1 mg/dl) and -triglycerides (28.9 +/-18.9 mg/dl) were within the normal range. No significan correlation was found between plasma triglyceride levels and plasma lipoprotein lipase activity (r=0.38, p greater than 0.2), and H-TGL activity, at 24.1 +/-9.3 mumol/ml FFA, was not different from control. In contrast to the complete normalization of LDL-cholesterol level, the HDL-cholesterol level remained slightly above control (HDL-cholesterol: 57.0 +/- 17.6 mg/dl). The hyperlipoproteinaemia in NS represents a combination of an increasents a combination of an increased hepatic lipoprotein synthesis and a decreased catabolism of triglyceride rich lipoproteins as indicated by an insufficiency of the lipoprotein lipase. The simultaneous elevation of LDL- and HDL-cholesterol suggests at most a moderate degree of atherogeneity of the hyperlipoproteinemia in NS.

Adolescent↗
PubMed1979

[Procetophen--an alternative in the treatment of hypercholsterinemia?].

18 patients with primary hyperlipoproteinemia of type IIa and type IIb, on regularly controlled dietary treatment for 6 months and a 4 weeks placebo period, were given 300 mg procetofene per day for 12 weeks. The subjective tolerance of the drug was good. The serum triglyceride levels were lowered by about 35%, total cholesterol by 15%, LDL-cholesterol by 12% and Apo B by 20%. The HDL-cholesterol values remained unchanged. A slight increase in SGPT values indicates that liver function should be regularly checked in patients undergoing procetofene therapy.

Adult↗
PubMed1979

Blood pressure and adipose tissue linoleic acid.

In a natural, "free-living population" of 650 men, surveyed with the purpose of health assessment within an epidemiological design, a strongly significant negative correlation between the relative linoleic acid composition of adipose tissue and blood pressures was found (P less than 0.001). This correlation remained significant when age and weight were statistically controlled for. Thus, dietary, lipid-lowering linoleic acid seems to effect blood pressures as well in a favorable way.

Adipose Tissue↗